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Purpose: Septic acute kidney injury (AKI) is associated with poor outcome. This can partly be
attributed to delayed diagnosis and incomplete understanding of the underlying pathophysiol-
ogy. Our aim was to develop an early predictive test for AKI based on the analysis of urinary
peptide biomarkers by MALDI-MS.
Experimental design: Urine samples from 95 patients with sepsis were analyzed by MALDI-
MS. Marker search and multimarker model establishment were performed using the peptide
profiles from 17 patients with existing or within the next 5 days developing AKI and 17 with
no change in renal function. Replicates of urine sample pools from the AKI and non-AKI
patient groups and normal controls were also included to select the analytically most robust
AKI markers.
Results: Thirty-nine urinary peptides were selected by cross-validated variable selection to
generate a support vector machine multidimensional AKI classifier. Prognostic performance
of the AKI classifier on an independent validation set including the remaining 61 patients of the
study population (17 controls and 44 cases) was good with an area under the receiver operating
characteristics curve of 0.82 and a sensitivity and specificity of 86% and 76%, respectively.
Conclusion and clinical relevance: A urinary peptide marker model detects onset of AKI with
acceptable accuracy in septic patients. Such a platform can eventually be transferred to the
clinic as fast MALDI-MS test format.
Keywords:
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1 Introduction
The reported incidence of acute kidney injury (AKI) asso-
ciated with sepsis is steadily increasing, estimated at 2.8%
per annum [1]. This is due to an increase of comorbidity
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conditions and the severity of illness [1]. Whereas in hospi-
tal mortality rate for AKI decreased from 41.3% in 1988 to
28.1% in 2002 [2], there is an increasing concern that AKI is
associated with later development of chronic kidney disease
(CKD) [3–7].
The severity of AKI also has a direct effect on the out-
comes and even small increases in serum creatinine levels
are inversely related to long-term survival of patients, length
of hospital stay, and costs [8]. Overall, little progress has been
made in AKI management and its associated complications
so that the overall outcome remains grim [1, 9, 10].
There are several explanations for the lack of progress in
the field of septic AKI. Serum creatinine only starts to rise
hours after the initial insult to the kidney [11]. Moreover, it
is a functional parameter that can also increase physiologi-
cally, e.g. in case of dehydration. During sepsis, creatinine
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Clinical Relevance
There is a clinical need for new biomarkers enabling
a more accurate and timely detection of septic acute
kidney injury (AKI) which in turn might lead to an
improvement in both short and long-term outcome.
The reported incidence of sepsis and hence sep-
tic AKI is steadily increasing. However, relatively
little progress has been made in its management,
and outcome remains grim. Relying on existing sin-
gle component biomarkers for early AKI diagnosis,
has proven to be disappointing because these sin-
gle biomarkers are unable to capture the complex
pathophysiological process of septic AKI. A panel
of biomarkers might be more appropriate for this
purpose and allow for earlier diagnosis of septic AKI
compared to single biomarkers and standard param-
eters such as serum creatinine and urinary output.
We have previously identified a panel of biomarkers
by using CE-MS. By using this panel, we could detect
AKI 5 days earlier than existing biomarkers. How-
ever, CE-MS is a highly specialized research tool that
is not suited for daily clinical practice. Our aim was
to develop an early predictive test for AKI based on
the analysis of urinary peptide biomarkers byMALDI-
MS. Such a platform can be transferred to the clinic
as point-of-care test to provide timely detection of
septic AKI to improve clinical outcome.
production is reduced, and the distribution volume increased
due to capillary leakage and fluid overload [12], which can
further add to the delay in diagnosis [13]. These observations
have encouraged the quest for new biomarkers that might
allow diagnosis at an earlier stage. However, results have
been inconsistent [14,15], and it is still unclear whether these
biomarkers do have any relevance in clinical management of
patients.
The pathophysiology of septic AKI is largely unknown
[16–18]. In addition, in most cases, there is no clear timing
of renal insult. The appearance of biomarkers is time related
and thus the window for biomarker detection can easily be
missed. Therefore, there might be no single biomarker able
to capture the complex pathophysiological processes of septic
AKI. A clinical review of 12 existing biomarkers for AKI in-
cluding cystatin C, neutrophil gelatinase-associated lipocalin
(NGAL), and kidney injurymolecule 1 found their discrimina-
tory power to be poor, with AUC’s ranging from 0.5 to 0.8 [2].
A panel of biomarkers might offer advantages for AKI detec-
tion [19]. Such a panel might offer a better pathophysiological
understanding and provide insights in the pathophysiological
link between AKI and later CKD, which affects a substantial
proportion of AKI patients [4, 20].
We have previously demonstrated that by using CE-MS
we could identify a urinary peptide marker profile that per-
formed better than traditional and single biomarkers for early
AKI diagnosis in intensive care patients [19]. The drawback
of CE-MS is that the time requirement (>24 h), the high skill
operating level and high cost make it impractical for close
monitoring of acute events and point of care testing in daily
clinical practice. Analysis of peptides can also be carried out
using MALDI-MS that is a higher throughput, less expen-
sive and less skilled approach [21]. Hence, the MALDI-MS
platform is currently more suitable than CE-MS for the im-
plementation of fast screening assays in daily clinical practice
providing a test result within a few hours.
In this study, we aimed to use the MALDI-MS platform
in a cohort of sepsis patients to identify a marker panel for
timely AKI diagnosis. This might lead to a better outcome in
sepsis patients, by limiting fluid overload [22,23] and prevent-
ing further renal damage through avoidance of nephrotoxic
drugs [24].
2 Materials and methods
2.1 Patients and samples
The urinary low molecular weight proteome of 95 out of
195 septic patients enrolled in the clinical trial NCT01981993
and admitted to the Ghent University Hospital between
12/01/2010 and 27/03/2011 was analyzed byMALDI-MS. For
patient selection in this nested case–control study, patients
of the original study were grouped into AKI cases and con-
trols and within these groups randomly selected for MALDI
analysis using the random sample generator of MedCalc
11.4.1.0 (Mariakerke, Belgium). We defined sepsis, severe
sepsis and septic shock according to the American College of
Chest Physicians/Society of Critical Care Medicine Consen-
sus Conference [25]. AKI was defined according to the risk,
injury, failure, loss of kidney function, and end-stage renal
disease (RIFLE) guidelines [26] based on both serum creati-
nine and urinary output criteria within the first 5 days after
admission. Written informed consent was obtained from all
patients and ethical approval was obtained from the Ghent
University Hospital ethics committee. The study conformed
to the Helsinki Declaration standards.
Urine samples were collected from the urinary catheter
within 12 hours after intensive care unit (ICU) admission
and after transfer to a 10 mL-Monovette immediately frozen
and stored at –80C until analysis. From the 95-patient set,
17 patients with and 17 patients without onset of AKI were
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Table 1. Clinical and demographic data of the sepsis patients with (case group) or without (control group) AKI progression included in the
training and test sets of the case–control study for MALDI AKI model establishment
Parameter Training sets Test sets
AKI Non-AKI pb) AKI Non-AKI pb)
Patients/samples (n) 17/17 17/17 44/44 17/17
Age (years)a) 62 (39–81) 58 (18–83) 0.65 62 (24–89) 57 (17–77) 0.33
Gender male (%) 52.9 64.7 0.73 40.9 52.9 0.57
APACHE II score during the first
24h after ICU admissona)
22 (15–32) 20 (12–36) 0.24 25 (9–41) 19 (1–28) 0.03
Serum creatinine at ICU
admission (mg/dL)a)
0.83 (0.42–1.32) 0.85 (0.34–1.79) 0.58 0.85 (0.27–2.20) 0.90 (0.55–1.31) 0.32
Historical baseline CKD-EPI
(ml/min/1.73m2)a)
87.3 (55.8–124.2) 95.7 (38.4–149.2) 0.37 89.6 (26.2–195.4) 82.7 (44.1–115.2) 0.41
AKI as defined by RIFLE at the
first day of admission, No
AKI|R/I/Fcc) (%)
0|41/53/6 100|0/0/0 <0.0001 0|23/45/32 100|0/0/0 <0.0001
CKD on admission, CKD-EPI <
60 mL/min/1.73m2 (%)
5.9 11.8 1.00 9.1 11.8 1.00
Mortality rate, after 3 mo/1 y/2 y
(%)
35.3/35.3/35.3 29.4/52.9/64.7 0.04 31.8/45.5/59.1 23.5/41.2/52.9 0.84
Need for RRT during ICU (%) 11.8 0.0 0.48 15.9 0.0 0.17
Sepsis stage, sepsis/severe
sepsis/septic shock (%)
0/18/82 0/59/41 <0.0001 11/41/48 0/53/47 0.002
CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; ICU, intensive care unit; MDRD, modification of diet in renal
disease; RIFLE, risk/injury/failure/loss of kidney function/end stage renal disease; RRT, renal replacement therapy.
a) Given as mean (range).
b) Two-tailed probability for continuous data and significance level by Fisher’s exact test or chi-square test for categorical data.
c) Risk/injury/failure of kidney function.
randomly selected as a training group for statistical AKI
biomarker search and multimarker model establishment,
whereas all remaining patients were used as test groups for
validation of the peptide marker model. Clinical and demo-
graphic characteristics of the AKI and non-AKI patients in-
cluded in the training and test groups are given in Table 1.
Urine sample pools from ten normal individuals, seven
septic patients without AKI and seven septic patients with
AKI were repeatedly analyzed at one defined time point.
Replicates of these sample pools were included in the train-
ing phase to identify analytically robust AKI markers and for
variance stabilization of the MALDI marker pattern. During
the test phase, replicates of these sample pools were used to
determine test precision and to calculate the variance of a
negative and positive test result. Another urine pool from
seven AKI case and seven non-AKI control patients was ana-
lyzed weekly over an 11-week period to determine long-term
reproducibility of the MALDI test. Finally, four case and con-
trol samples were analyzed daily to evaluate reproducibility
of individual samples.
2.2 Sample preparation for MALDI-MS
Urine samples were prepared as previously described [27].
Serial dilutions of each sample, which covered two or-
ders of magnitude (0.35–0.0035 L equivalents of urine)
were prepared with 0.1% TFA. Protein concentration was
determined by Bradford analysis to be in the range of
13–35 ng/L. Twelve dilutions were then spotted on a 384
well MTP Anchorchip (Bruker Daltronics, Bremen, Ger-
many) target plate in quadruplicate [28]. One microliter of
sample was left to dry on the target plate, followed by 1 L of
a 5mg/mL of -cyano-4-hydroxycinnamic acid (CHCA)ma-
trix (Laser Biolabs, Sophia-Antipolis, France). Thematrix con-
centration was previously determined to be the optimum us-
ing standard urine dilution series. No internal standards were
added for quantification purposes as this has been shown to
be ineffective [28].
2.3 MALDI MS analysis
UntargetedMALDI-MS peptide profiling was performed on a
ShimadzuAximaConfidence (Kratos,Manchester, UK)mass
spectrometer in reflectron-positive ion mode. For each sam-
ple spot, 36 profiles with 50 laser shots/profile and a laser
power between 50 and 56 were carried out. The laser repe-
tition rate was set to 50 Hz that together with an ion gate
of 800 Da allowed the detection of peptide signals over a
mass range of 100–4000 m/z. For peak processing, the peak
clean up settings were based on a peak width of five, a Gaus-
sian smoothing filter width of two and a baseline subtraction
filter width of six. The peak detection method utilizes a 25%-
centroid arched threshold, an offset of 0.2 mV and a onefold
response factor. Monoisotopic peak picking was performed
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by the Poisson peptide method [29] with a peak picking
minimum and maximum mass of 800 and 3900 m/z, re-
spectively. External mass calibration using bovine serum al-
bumin peptides (Life Technologies) as standards was per-
formed every four spots. For the eight BSA peptides (mass
range: 927.493–2045.028 m/z) the maximum allowed mass
accuracy variation was adjusted to 10 ppm.
2.4 MALDI-MS data processing, data merging, and
regression analysis
MALDI-MS data were exported as peak lists using Shi-
madzu’sMALDI-MS Launchpad v2.9.3 software. MALDI-MS
peak intensity data were analyzed in fully automated mode
using an improved version (version v5d) of the IAMA soft-
ware [28]. Briefly, all sample data were automatically loaded
into spreadsheets and normalized by tallying the intensities
by each sample and then dividing each value by the total inten-
sity. Technical replicates were combined using a minimum
of three observed peaks per sample and peak as threshold. A
regression line was calculated based on the dilutions of every
single original sample for every single peak. The algorithm
was set to remove any outliers from the dilution rows until a
minimum of 20 was reached by recalculating the regression
line and the perpendicular distance of each data point from
the regression line. Peaks that were not observed in at least
three dilution samples per original samplewere automatically
rejected.Only peak data dilution series resulting in regression
lines with a negative slope were passed. The output was set
to report the projected values using a dilution factor of one
for each peak in every original sample, and the associated
statistical output such as coefficient of determination (R2),
F distribution and standard errors were suppressed.
2.5 Biomarker definition and support vector
machine (SVM) model generation
p values for peptide distribution differences between the AKI
case and non-AKI control training groups of sepsis patients
were calculated based on natural logarithm transformed in-
tensities and the Wilcoxon rank sum test. A SVM-based clas-
sification model was constructed with a preceding feature
selection step based on cross-validation using the MosaClus-
ter software as previously described [30].
3 Results
3.1 Patient characteristics and clinical data
We analyzed urine samples from 95 out of 195 randomly se-
lected sepsis patients from the clinical trial NCT01981993 by
MALDI MS. The demographic and clinical data of the AKI
case and non-AKI control patients included in the training
and test sets is presented in Table 1. Only the severity of sep-
sis showed markedly significant differences between the AKI
and non-AKI groups in both the training and test sets. For
the 95 randomly selected patients, the same characteristics
as for the whole 195 patient set of the clinical trial were ob-
served for the frequency of AKI occurrence (p= 0.60), gender
(p= 0.37), age (p= 0.47), and serum creatinine levels at base-
line (p = 0.32).
3.2 MALDI analyses and MALDI-MS data processing
Each urine spot on the MALDI plate produced on average
5000 ± 105 features that were filtered to gain a total list
of 1149 peptides in the mass range of 800–3100 Da with
a frequency distribution in MALDI samples of >10%. In
the subsequent statistical analysis for biomarker selection
the number of MALDI-MS-identified peptides was further
restricted to a number of 937 with a frequency distribu-
tion >25% in at least one of the AKI and non-AKI patient
groups.
3.3 Peptide marker identification and multimarker
model generation
Out of the 51 peptides that were significant in Wilcoxon rank
sum statistics 39 were selected via cross-validation. Prefer-
entially those markers were selected that could be detected
with low amplitude variability in the 12 replicates of the sam-
ple pools. The biomarker model developed by this strategy is
presented in Table 2. Based on these 39 peptides, a SVM clas-
sifier was constructed in the 17 AKI case and non-AKI control
samples of the training set including also 12 replicates of the
urine sample pools.
3.4 ROC analysis and model validation
The model’s accuracy to distinguish between AKI cases and
non-AKI controls was first evaluated by receiver operating
characteristics (ROC) analysis after leave-one-out total cross-
validation on the original training set consisting of 17 AKI
case and 17 non-AKI control patients and by including 12
replicates of the sample pools. This resulted in an area under
the ROC curve (AUC) value of 0.90 (95% confidence inter-
val (CI): 0.77–0.97; p < 0.0001). At a classification threshold
> –0.05, 14 out of 17 AKI case samples and all four repli-
cates of the AKI patient pool scored positive, whereas 13 out
of 17 non-AKI controls and six from eight replicates of the
non-AKI patient and normal control pools scored negative for
AKI. This resulted in sensitivity and specificity values of 86%
and 76%, respectively (Fig. 1A). The criterion for selection
of –0.05 as cut-off was based on the rationale to obtain the
highest level of sensitivity (>85%) at a still acceptable level
of specificity (>75%). The model was subsequently tested in
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Figure 1. Classification performance characteristics of the MALDI marker pattern for detection of AKI in sepsis patients. (A) ROC curve for
the training set of 17 AKI case and 17 non-AKI control samples after total cross-validation (left panel). The 12 replicates of urine sample
pools from normal controls, AKI cases and AKI controls (four of each pool) that were used in the training phase for variance stabilization
of the classifier were also included in this ROC analysis. ROC curve for the independent test set consisting of 44 AKI case (with balanced
distribution of sepsis and AKI stages) and 17 control samples (right panel). The point estimates of the model’s classification scores at
different thresholds are given as thick continuous lines, whereas the 95% confidence intervals (CI’s) are indicated by thin dashed lines.
The table presents the quality characteristics of the ROC analysis for both the training and test sets. For P-value calculation the departure
of the classifiers AUC from 0.5 (a random classifier) was assessed by using a standard t-test. (B) Box-and-Whisker representation of the
classification scores for the 19 replicates of urine sample pools of normal controls, AKI cases and AKI controls used in the studies validation
phase to evaluate the models classification stability and to calculate the variance in the probability distribution of a negative and positive
test result for these patient groups by the MALDI marker pattern. (C) Time-resolved diagram for repeated classification of an AKI control
and AKI case sample pool in weekly intervals over an 11-week period. (D) Dot line diagram of four individual AKI cases and AKI controls
analyzed one day apart to evaluate the reproducibility of the sample preparation and instrumentation. Duplicates of the individual samples
are connected by a dashed line. In (B) to (D) the classification cut-off at –0.05 is shown as dashed line.
the independent validation set consisting of 17 non-AKI con-
trols and 44 AKI cases. In the validation set the AUCwas 0.82
(95%CI: 0.70–0.91; p< 0.0001) that confirms that the peptide
marker model is highly significant for AKI leading to a sen-
sitivity of 86% and a specificity of 76% at the predetermined
cut-off of –0.05 (Fig. 1A). In comparison, the AUC’s for the
classical parameters estimated glomerular filtration rate and
serum creatinine levels at baseline in this test set of patients
were 0.58 and 0.59, whereas absolute urinary NGAL levels
and urinary NGAL-to-creatinine ratios resulted in AUC’s of
0.74 and 0.68, respectively.
In order to test the models classification stability the vari-
ance of a negative and positive test result was determined
using in total 19 replicates of the urine sample pools of nor-
mal controls and of patientswith orwithout AKI (repeatability
analysis). As presented in Fig. 1B, the variance for all sample
pools is in an acceptable range leading to no misclassifica-
tion. Along the same line, we were able to correctly classify
all replicates of the AKI case pool in the 11-week lasting
weekly analysis series. There were two misclassified control
replicates; the false-positive rate over the 11-week period was
therefore 18% (Fig. 1C). The dot and line diagram presented
C© 2016 The Authors. PROTEOMICS - Clinical Applications Published by WILEY-VCH Verlag GmbH & Co. KGaA www.clinical.proteomics-journal.com
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Figure 2. Dependency evaluation of AKI classification by the
MALDI marker pattern from the severity grade of sepsis on the
test set patient cohort (n = 61). The distribution of the AKI mod-
els classification scores within the groups of sepsis, severe sepsis
and septic shock are given as Box-and-Whisker plots. Sepsis stag-
ing was performed according to the American College of Chest
Physicians/Society of Critical Care Medicine Consensus Confer-
ence guidelines. Six patients were excluded due to missing sep-
sis severity grades. Differences between the groups were found
to be not significant in a Kruskal–Wallis rank sum test.
Figure 3. Dependency evaluation of AKI classification by the
MALDI marker pattern from the severity of AKI on the test set
patient cohort (n = 61). The distribution of the AKI models clas-
sification scores within the AKI groups of risk (stage 1), injury
(stage 2), and failure (stage 3) according to the RILFE criteria to-
gether with the non-AKI control group (stage 0) are given as Box-
and-Whisker plots. Differences between the groups were found
significant between stage 0 and the stages 1–3 in a Kruskal–Wallis
rank sum test.
in Fig. 1D shows the classification scores of duplicate analy-
sis of eight individual samples, four from AKI case and four
from non-AKI control patients at two consecutive days. In
this analysis, there was one false positive and no false nega-
tive classification.
The sepsis stage is not a confounding factor for AKI de-
tection by MALDI (Fig. 2, Kruskal–Wallis rank sum test).
As presented in Fig. 3, the MALDI marker model correctly
predicted the onset of AKI without rank differences between
the RIFLE stages 1–3.
3.5 Sample size justification
Assuming normal distribution of the AUC value it was es-
timated that inclusion of 17 AKI case and non-AKI control
patients in the training set was sufficient to show superiority
of the proteome marker model (AUC of 0.82) in comparison
to the classical parameters estimated glomerular filtration
rate (AUC of 0.58) and serum creatinine levels at baseline
(AUC of 0.59) in the test set at a 5%-level of type one errors
and 80% statistical power.
3.6 Peptide sequence identification
Direct sequencing of peptides in the MALDI MS relies on
mass accuracy of the data alone. However, by also analyz-
ing the samples using CE-MS, additional information, which
adds to the confidence in matching peptides to previously
identified sequences can be obtained.
Therefore, the samples were also analyzed by CE-MS and
the CE-MS peptide profiles specifically examined for the oc-
currence and distribution of the 39 MALDI marker peptides.
From the peptides included in the MALDI marker pattern,
nine could also be identified to be differentially regulated in
CE-MSpeptide profileswith p-values below 0.05 in the respec-
tive Wilcoxon rank sum-based statistical group comparison.
Besides validation of the peptidemarkers on anotherMS plat-
form, matching of the peptides to the 2D CE-MS profiles car-
ries the additional advantage that with the CEmigration time
an additional peptide-characteristic could be determined for
the nine AKI marker peptides detected by both MS methods.
This is especially advantageous for the identification of the
amino acid sequence of the peptides since the CE migration
time is related to the number of positive charges and allows by
the specific line pattern of a CE-MS spectrum the calculation
of the number of basic amino acids inside the peptides amino
acid sequence. Via CE-MS cross-reference and by a search in
our peptide sequence database [27], it was possible to resolve
the sequence of seven out of the 39 peptides included in the
MALDI marker pattern. The peptides from the MALDI AKI
marker pattern of which the amino acid sequences could be
retrieved by this strategy are presented in Table 3.
3.7 Comparison to CE-MS-based classification
For a subset of 36 AKI case and 16 non-AKI control samples
peptide profiles from both MALDI and CE-MS are available.
Classification of this subset by the 20-peptide marker panel
for AKI prediction in CE-MS resulted in only poor classifi-
cation performance with the AUC being at 0.55 (95% CI:
0.40–0.69). In contrast, a better differentiation of AKI ver-
sus non-AKI in this sepsis patient cohort was possible if the
C© 2016 The Authors. PROTEOMICS - Clinical Applications Published by WILEY-VCH Verlag GmbH & Co. KGaA www.clinical.proteomics-journal.com
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CKD-specific CE-MS model was applied, the AUC being at
0.79 (95% CI: 0.65-0.89). In the case were the MALDI and the
CKD CE-MS classifier were combined by logistic regression
an AUC of 0.94 (95% CI: 0.83–0.99) was obtained resulting
in a sensitivity and specificity of 92 and 88% at the Youden
index of 0.54 as logistic regression score.
4 Discussion
There is a clinical need for new biomarkers to allow for amore
accurate and timely detection of AKI in order to improve short
and long-term outcome. In septic AKI, with no clear timing of
renal insult, a panel of biomarkersmight bemore appropriate
to capture this complex pathophysiological process and to
allow for a more accurate and early diagnosis compared to
serum creatinine and urinary output. We identified a marker
panel of 39 peptides thatwas highly predictive of AKI in sepsis
by using a MALDI-MS platform.
Establishment of the MALDI peptide marker panel was
based on a SVM learning algorithm. Briefly, SVMs for su-
pervised learning recognize patterns, which they can trans-
form to numerical membership values. Given a set of train-
ing data, marked as belonging to one of two classes (here
the AKI case and the AKI control group), the SVM training
algorithm builds a high-dimensional parameter space with
one dimension represented by one peptide marker (n pep-
tides thus equals n dimensions). Within this n-dimensional
space, the samples are ordered according to the peptide’s
log-transformed amplitudes and a separation hyperplane is
drawn bymaximizing themargin between opposite positions
of the case and control data points. After establishment of
the SVM classifier, new samples are assigned to either the
case or control group according to the degree of similarity
in their peptide marker profiles. SVM-based multimarker
models have shown promising results, and we previously
demonstrated that by using a panel of 20 peptides we could
improve classification of AKI versus non-AKI ICU patients
with high sensitivity and specificity [19]. However, the CE-MS
platform used in this study is currently not suited for daily
clinical practice. MALDI-MS theoretically offers the advan-
tage of high throughput, is fast and cost effective and does
not require highly trained staff to operate it.
MALDI-MS has previously been used to detect biomark-
ers for diagnosis and prognosis of a range of clinical disor-
ders such as hepatocellular carcinoma, hepatoblastoma, and
pancreatic cancer [31–33]. Furthermore, MALDI instrumen-
tation is becoming more widely available in clinical settings
for rapid identification of pathogens [21]. However, a num-
ber of studies have identified a range of problems with data
quantification and reproducibility of results in protein stud-
ies [34, 35], questioning the advantages of this platform for
clinical proteomics use.
We have previously reported on a method to improve the
relative quantification of MALD-MS analysis for proteomic
biomarker assessment [28]. A further development on the
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method used in the original MALDI study was the elution
of the peptides from the desalting columns in 0.1% TFA, al-
lowing direct spotting onto the MALDI plate for immediate
analysis. The technique of spotting a range of dilutions of the
sample onto the MALDI plate and then using an algorithm
to identify the linear range of individual peptides for quan-
tification provides a simple solution to the aforementioned
problems. In addition, the software for quantitative analysis
by MALDI was further developed to allow automated data
evaluation. In AKI samples from patients with sepsis, we de-
veloped a biomarker model made up of a panel of 39 urinary
peptides. Applying this model to the test set containing 44
cases and 17 controls produced an AUC of 0.82 (p < 0.0001)
with a sensitivity of 86% and specificity of 76%. Although
CE separation of peptides prior to MS analysis would result
in higher numbers of detected peptides and would allow via
lower interference of signal peaks for a better relative quantifi-
cation of single peptides [28, 36], the MALDI-MS biomarker
developed here compares well alongside the state of the art
CE-MS biomarkers.
During development of the MALDI test, it became obvi-
ous that replicates of AKI case and non-AKI control sample
pools had to be included to ensure reproducibility in sample
classification. This was a crucial step in respect to identify
the most robust peptide markers and to variance stabilize the
multimarker model in the SVM learning phase.
Also of great interest was to determine how well classifi-
cation by the MALDI-MS marker pattern is associated to the
assessment of the patients on admission with their RIFLE
scoring. With a cut-off value of –0.05, the MALDI-MSmarker
is correctly predicting AKI even when the RIFLE assessment
score is at stage 1.
Only sevenout of the 39peptidesmakingup themodel had
sequence information available. The identified peptides are
fragments from the collagen chains alpha-1(I) (COL1A1) and
alpha-1(II) (COL1A2), alpha-1-antitrypsin (SERPINA1), beta-
2-microglobulin (B2M), and fibrinogen alpha chain (FGA).
In comparison to the 20-peptide marker pattern for AKI
prediction in CE-MS [19], COL1A1, SERPINA1, B2M, and
FGA could be reproduced by MALDI as AKI-specific pep-
tide marker source. Direct comparison of the two marker
patterns revealed identity of the SERPINA1-derived peptide
SERPINA1[Thr363-Phe376], whereas the COL1A1-, B2M-,
and FGA-derived AKI peptide markers in MALDI are for
the most part smaller fragments of the previously de-
scribed CE-MS-identified peptide markers. This accounts
for the peptides B2M[Asn62-Lys68], COL1A1[Ser546-Ala559]
and FGA[Asp605-Lys620] inMALDI with B2M[Leu60-Ser81],
COL1A1[Thr541-Gly560], and FGA[Asp605-Arg621] as CE-
MS counterparts. In this context, it must be noted that the de-
tected mass range in MALDI-MS is generally more restricted
to smaller sized peptides (0.8–3.2 kDa) compared to the one
in CE-MS (0.8–16.0 kDa).
The seven MALDI AKI peptide markers known by se-
quence were also compared to the 273 CKD-peptide mark-
ers described by Good et al. [27]. In this case, there was an
overlap of three peptides affecting the peptides SERPINA1
[Thr363-Phe376], COL1A1[Ser546-Ala559], and FGA[Asp605-
Lys620].
In accordance to our previous study on AKI peptide mark-
ers in urine by CE-MS [19], further support is given to the
hypothesis that increased urinary levels of peptide fragments
derived from the blood proteins B2M and SERPINA1, and
decreased urinary levels of FGA are early signs of AKI. With
regard to the collagen alpha-1(I) and alpha-1(II) chain struc-
tural proteins, peptide fragments thereof were found to be
either down- or upregulated in AKI compared to non-AKI
sepsis patients. Differential excretion of collagen alpha chain-
derived peptide fragments was already described in a number
of other proteomic studies on CKD andAKI [19,27,37,38] and
is indicative for alterations in extracellular matrix turnover
[39,40], i.e. via tumor necrosis factor alpha-induced activation
of matrix-degrading proteases [41,42]. Alterations in extracel-
lular matrix turnover in turn were interpreted as a possible
trigger factor in the development of CKD [43]. Therefore,
the peptides identified in this study link particularly well to
the current pathophysiological concept of AKI that might
explain their good performance—as a panel—to predict
AKI.
Efforts are now underway to resolve the amino acid se-
quence of all remaining unidentified peptidemarkers by post-
source decay mass spectrometry. If the multimarker model
is only restricted to the sequence identified peptide mark-
ers this resulted in only moderate classification performance
with the AUC being 0.72 (95% CI: 0.59–0.83) demonstrating
the requirement to also include the yet unidentified peptides
in the classification model.
The use of MALDI-TOF analysis for clinical biomarker
assessment has not previously been possible due to the poor
quantitative nature of the technique [44]. We previously pre-
sented methodology and software solution to these problems
[28] and now present data on their application to biomarker
model development. The 39-peptide marker panel of sepsis-
induced AKI provides a significant improvement in sensitiv-
ity and selectivity over single marker tests.
In contrast to the MALDI AKI peptide marker pattern,
our previously established 20-peptide marker pattern for AKI
prediction of CE-MS peptide profiles failed to reliably detect
AKI in this cohort of sepsis patients. Since when applying
CE-MS a CKD-specific peptide marker profile enabled bet-
ter differentiation of AKI from non-AKI, we hypothesize that
in the study cohort of sepsis patients those with AKI more
likely contain features related to the CKD rather than the AKI
CE-MS peptide profile. Even in the initial phase, pathways re-
lated to CKD might therefore be active in this sepsis patient
collective. According to the finding that the combination of
the MALDI and CKD CE-MS tests by logistic regression sig-
nificantly improves classification accuracy, a strategy where
MALDI-positive patients are subsequently reassessed by the
CKD CE-MS classifier might be considered in the future to
further improve diagnosis of septic AKI and its progression
to CKD in the clinical setting.
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The limitation of the study is that it describes a proof-of-
concept study on a relatively small population of 95 sepsis
patients evaluating if an AKI-specific peptide marker pattern
with performance characteristics similar to the one already
established for CE-MS is also possible forMALDI-MS peptide
profiles. For this specific aim, the group of selected patients
is well defined and the diagnosis of AKI by RIFLE is based on
both the serum creatinine and the urinary output criterion.
A historical baseline serum creatinine value was available for
all patients.
The analytical reproducibility of MALDI analysis in a clin-
ical setting has been questioned and discussed [44]. To access
the long-term stability of the biomarker model and also to
address the MALDI instrumentation reproducibility we un-
dertook to analyze pools of samples over an 11-week period.
In this series, we correctly classified all of the AKI case pool
replicates. Two AKI control replicates in the 11-week series
were classified positive, which resulted in a false-positive rate
of 18%. Although this is still evaluated to be in an accept-
able range, efforts were made to identify the reason for this
tendency toward false-positive classification. We found that
despite frequent calibration checks, the laser output power
in the instrument varied over time and was not consistent
at the settings selected within the method file. An increase
in laser output can increase the noise level in the signal
to a point where "noise" peaks were recorded as real pep-
tide signals leading to a higher false-positive rate. Inclusion
of the laser output power in the calibration method that is
currently under nonmodifiable software control is in our
opinion an essential step to further improve the diagnos-
tic accuracy of our MALDI test for its use in a daily clini-
cal setting to repeatedly monitor AKI progression in sepsis
patients.
4 Conclusion
Wehave developed and tested a newurinary biomarkermodel
for septic AKI that demonstrates sufficient sensitivity, speci-
ficity, and classification stability to allow for significant im-
provement in timely detection of AKI. The MALDI-MS plat-
form for this test is similar to the one already available in the
nonresearch setting [21], and the timeframe and per sample
cost are in keeping with those required for daily clinical use.
The next crucial step would be to demonstrate a significant
benefit of this biomarker panel in a prospective clinical study,
which is currently being planned.
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